
Opinion|Videos|January 2, 2025
Utilizing Safety Data When Prescribing Ruxolitinib Cream for Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD
The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Updates iPLEDGE REMS with New Modifications for Pregnancy Testing and Prescription Windows
2
New Phase 3 DISCREET Data Supports Long-Term Use of Apremilast for Genital Psoriasis
3
Rethinking Aging in Skin of Color: A Pigment-First Approach
4
Phase 3 Results Signal a New Era for Oral Targeted Therapy in Psoriasis
5














